6
Medicinal Chemistry, 2010, 6, 6-8
Synthesis and Preliminary Biological Evaluation of Chrysin Derivatives as
Potential Anticancer Drugs
Xing Zheng1,*, Fei Fei Zhao1, Yun Mei Liu, Xu Yao, Zi Tong Zheng, Xing Luo and
Duan Fang Liao
Institute of Pharmacy & Pharmacology, University of South China, Hengyang 421001, China
Abstract: A series of chrysin derivatives were prepared from 2-hydroxyacetophenone, 2,4-dihydroxyacetophenone, 2,4,6-
trihydroxy- acetophenone, using modified Baker-Venkataraman transformation. Their anticancer activities in vitro were
evaluated by the standard MTT method. The results of biological test showed that some of chrysin derivatives showed
stronger anticancer activity than 5-fluorouracil.
INTRODUCTION
acetate gave 5-methoxy-flavones 4a-4c and 5,7-dimethoxy-
flavones 4d-4h, respectively. Reaction of 2-hydroxy-
acetophenone 2c with substituted benzoyl chlorides followed
by the flavone ring formation in same conditions gave the
flavone analogues 4i-4m.
Chrysin, a natural flavonoid widely distributed in plants,
has been reported to have various biological activities such
as anticancer [1], anti-inflammatory [2], anti-oxidant [3],
anti-anxiolytic [4], vasodilatory actions [5]. In anticancer
area, chrysin has been found to possess anti-proliferative
activity through inhibiting malignant cell growth by down-
regulated expression of PCNA in Hela cells [6], and induced
apoptosis through caspase activation and Akt inactivation in
U937 cells [7]. However, the anticancer activity of chrysin in
vivo studies on animals and humans has been disappointing
mainly due to extremely poor oral bioavailability [8]. The
crucial feature of chrysin in this respect is their unprotected
hydroxyl groups, which are rapidly and efficiently metabo-
lized via glucuronidation and sulfation [9]. As a part of our
current work on the search for anticancer substances with
high efficacy, low toxicity and minimum of side effects [10-
12], herein, we describe the synthesis of chrysin derivatives
and their anticancer activities against human gastric carci-
noma SGC-7901, human colon cancer HT-29, and human
promyelocytic leukemia HL-60 cell lines.
All the new compounds were characterized by detailed
o
spectroscopic analysis. 4a White powder, mp 142-143 C.
HRFABMS m/z 321.0733 [M+H]+ (C17H11F3O3, calc.
321.0738). IR (cm-1, KBr): 1365, 1438, 1501, 1589, 1613,
1642(C=O), 2948, 2976; 1H NMR (300MHz, CDCl3):
3.967(3H, s), 6.815(1H, s), 7.007-7.047(2H, m), 7.648-
7.701(1H, m), 7.791-7.817(1H, m), 8.065-8.091(1H, m),
8.139-8.171(1H, m), 8.194(1H, s). 4d White powder, mp
156-157 oC. HRFABMS m/z 351.0839 [M+H]+ (C18H13F3O4,
calc. 351.0844). IR (cm-1, KBr): 1390, 1437, 1460, 1489,
1
1602, 1614, 1653(C=O), 2945, 2971; H NMR (300MHz,
CDCl3): 3.942(3H, s), 3.973(3H, s), 6.308(1H, d, J = 2.1Hz),
6.718(1H, d, J = 2.1Hz), 6.745(1H, s), 7.617-7.670(1H, m),
7.760-7.788(1H, m), 8.023-8.050(1H, m), 8.150(1H, s). 4f
o
White powder, mp 186-187 C. HRFABMS m/z 317.0586
[M+H]+ (C17H13O4Cl, calc. 317.0580). IR (cm-1, KBr): 1417,
1
1459, 1487, 1584, 1605, 1660(C=O), 2847, 2944; H NMR
(300MHz, CDCl3): 3.920(3H, s), 3.964(3H, s), 6.392(1H, d,
J = 2.4Hz), 6.566(1H, d, J = 2.4Hz), 6.653(1H, s), 7.454-
7.500(2H, m), 7.788-7.834(2H, m). 4h White powder, mp
SYNTHESIS CHRYSIN DERIVATIVES
Among the reported methods to synthesize flavonoids,
the Baker-Venkataraman transformation is a largely applied
one. The synthesis of compounds 4a-4m were carried out
according to modified Baker-Venkataraman transformation
(Fig. 1). Commercially available 2,4-dihydroxyacetophenone
1a and 2,4,6-trihydroxyaceto- phenone 1b were treated with
anhydrous potassium carbonate and dimethyl sulfate in ace-
tone to give 2a and 2b, respectively. 2a and 2b were reacted
with substituted benzoyl chlorides in the anhydrous potas-
sium carbonate in acetone to afford the corresponding 1,3-
diketones 3a-3c and 3d-3h, respectively. Treatment of 3a-3c
and 3d-3h with glacial acetic acid and anhydrous sodium
o
177-178 C. HRFABMS m/z 313.1076 [M+H]+ (C18H16O5,
calc. 313.1075 ). IR (cm-1, KBr): 1429, 1458, 1493, 1574,
1592, 1601, 1634(C=O), 2954; 1H NMR (300MHz, CDCl3):
3.900(3H, s), 3.933(3H, s), 3.958(3H, s), 6.367(1H, d, J =
2.1Hz), 6.535(1H, d, J = 2.1Hz), 7.012-7.060(2H, m), 7.082-
7.110(1H, m), 7.423-7.481 (1H, m), 7.853-7.885(1H, m) 4i
o
White needles, mp 146-147 C. HRFABMS m/z 291.0633
[M+H]+ (C16H9F3O2, calc. 291.0632). IR (cm-1, KBr): 1382,
1
1445, 1466, 1577, 1605, 1625, 1667(C=O), 3139; H NMR
(300MHz, CDCl3): 6.879(1H, s), 7.437-7.491(1H, m), 7.609-
7.831(4H, m), 8.090-8.120(1H, m), 8.202-8.268(2H, m).
BIOLOGICAL ACTIVITY
*Address correspondence to this author at the Institute of Pharmacy &
Pharmacology, University of South China, Hengyang 421001, China; Tel:
+86-734-8281408; Fax: +86-734-8281239;
All of the chrysin derivatives were tested for their anti-
cancer activity in vitro against HL-60, HT-29 and SGC-7901
cells by MTT-Based Assay, using 5-Fluorouracil as control.
E-mail :zhengxing5018@yahoo.com
1These two authors contributed equally to this article.
1573-4064/10 $55.00+.00
© 2010 Bentham Science Publishers Ltd.